Anti-platelet action of nitric oxide and selective phosphodiesterase inhibitors

M. Kurt Sly, Robert C. Eberhart, Morton D. Prager

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Nitric oxide gas is a potent inhibitor of platelet aggregation, with an IC50 of 3.6 μM for rabbit platelets. Since the NO effect is mediated via increased cGMP, this in vitro study was undertaken to test the hypothesis that selective phosphodiesterase (PDE) inhibitors might enhance aggregation inhibition at lower NO concentrations. Because the cAMP-selective PDE III and the cGMP-selective PDE V are prominent in platelets, milrinone, a PDE III inhibitor, and zaprinast, a PDE V inhibitor, were tested alone and in the presence of NO for their effect on aggregation. Aggregometry was performed on rabbit platelet-rich plasma following addition of ADP as agonist. Milrinone alone gave an IC50 of 12.4 μM. With each agent set to give suboptimal inhibition of aggregation, the combination of milrinone (3-16 μM) and NO (2-10 μM) produced a greater effect than either agent alone. Zaprinast exhibited no effect on aggregation in concentrations up to 160 μM. However, adding zaprinast to 2 μM NO, which alone reduced aggregation ∼30%, produced a marked synergism in the inhibitory effect up to and including no observable aggregation. These results indicate that elevation of either cAMP or cGMP is sufficient to inhibit platelet function. The platelet cAMP concentration appears high enough to be inhibitory when degradation is suppressed by milrinone. However, basal cGMP levels must be increased by NO before the zaprinast effect is observed.

Original languageEnglish (US)
Pages (from-to)115-118
Number of pages4
JournalShock
Volume8
Issue number2
StatePublished - 1997

Fingerprint

Milrinone
Phosphodiesterase Inhibitors
Nitric Oxide
Blood Platelets
Type 3 Cyclic Nucleotide Phosphodiesterases
Type 5 Cyclic Nucleotide Phosphodiesterases
Inhibitory Concentration 50
Rabbits
Platelet-Rich Plasma
Platelet Aggregation Inhibitors
Adenosine Diphosphate
Gases
zaprinast

ASJC Scopus subject areas

  • Physiology
  • Critical Care and Intensive Care Medicine

Cite this

Sly, M. K., Eberhart, R. C., & Prager, M. D. (1997). Anti-platelet action of nitric oxide and selective phosphodiesterase inhibitors. Shock, 8(2), 115-118.

Anti-platelet action of nitric oxide and selective phosphodiesterase inhibitors. / Sly, M. Kurt; Eberhart, Robert C.; Prager, Morton D.

In: Shock, Vol. 8, No. 2, 1997, p. 115-118.

Research output: Contribution to journalArticle

Sly, MK, Eberhart, RC & Prager, MD 1997, 'Anti-platelet action of nitric oxide and selective phosphodiesterase inhibitors', Shock, vol. 8, no. 2, pp. 115-118.
Sly, M. Kurt ; Eberhart, Robert C. ; Prager, Morton D. / Anti-platelet action of nitric oxide and selective phosphodiesterase inhibitors. In: Shock. 1997 ; Vol. 8, No. 2. pp. 115-118.
@article{8bf4cf8bf3cf4a8f8492911192e8a2f1,
title = "Anti-platelet action of nitric oxide and selective phosphodiesterase inhibitors",
abstract = "Nitric oxide gas is a potent inhibitor of platelet aggregation, with an IC50 of 3.6 μM for rabbit platelets. Since the NO effect is mediated via increased cGMP, this in vitro study was undertaken to test the hypothesis that selective phosphodiesterase (PDE) inhibitors might enhance aggregation inhibition at lower NO concentrations. Because the cAMP-selective PDE III and the cGMP-selective PDE V are prominent in platelets, milrinone, a PDE III inhibitor, and zaprinast, a PDE V inhibitor, were tested alone and in the presence of NO for their effect on aggregation. Aggregometry was performed on rabbit platelet-rich plasma following addition of ADP as agonist. Milrinone alone gave an IC50 of 12.4 μM. With each agent set to give suboptimal inhibition of aggregation, the combination of milrinone (3-16 μM) and NO (2-10 μM) produced a greater effect than either agent alone. Zaprinast exhibited no effect on aggregation in concentrations up to 160 μM. However, adding zaprinast to 2 μM NO, which alone reduced aggregation ∼30{\%}, produced a marked synergism in the inhibitory effect up to and including no observable aggregation. These results indicate that elevation of either cAMP or cGMP is sufficient to inhibit platelet function. The platelet cAMP concentration appears high enough to be inhibitory when degradation is suppressed by milrinone. However, basal cGMP levels must be increased by NO before the zaprinast effect is observed.",
author = "Sly, {M. Kurt} and Eberhart, {Robert C.} and Prager, {Morton D.}",
year = "1997",
language = "English (US)",
volume = "8",
pages = "115--118",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Anti-platelet action of nitric oxide and selective phosphodiesterase inhibitors

AU - Sly, M. Kurt

AU - Eberhart, Robert C.

AU - Prager, Morton D.

PY - 1997

Y1 - 1997

N2 - Nitric oxide gas is a potent inhibitor of platelet aggregation, with an IC50 of 3.6 μM for rabbit platelets. Since the NO effect is mediated via increased cGMP, this in vitro study was undertaken to test the hypothesis that selective phosphodiesterase (PDE) inhibitors might enhance aggregation inhibition at lower NO concentrations. Because the cAMP-selective PDE III and the cGMP-selective PDE V are prominent in platelets, milrinone, a PDE III inhibitor, and zaprinast, a PDE V inhibitor, were tested alone and in the presence of NO for their effect on aggregation. Aggregometry was performed on rabbit platelet-rich plasma following addition of ADP as agonist. Milrinone alone gave an IC50 of 12.4 μM. With each agent set to give suboptimal inhibition of aggregation, the combination of milrinone (3-16 μM) and NO (2-10 μM) produced a greater effect than either agent alone. Zaprinast exhibited no effect on aggregation in concentrations up to 160 μM. However, adding zaprinast to 2 μM NO, which alone reduced aggregation ∼30%, produced a marked synergism in the inhibitory effect up to and including no observable aggregation. These results indicate that elevation of either cAMP or cGMP is sufficient to inhibit platelet function. The platelet cAMP concentration appears high enough to be inhibitory when degradation is suppressed by milrinone. However, basal cGMP levels must be increased by NO before the zaprinast effect is observed.

AB - Nitric oxide gas is a potent inhibitor of platelet aggregation, with an IC50 of 3.6 μM for rabbit platelets. Since the NO effect is mediated via increased cGMP, this in vitro study was undertaken to test the hypothesis that selective phosphodiesterase (PDE) inhibitors might enhance aggregation inhibition at lower NO concentrations. Because the cAMP-selective PDE III and the cGMP-selective PDE V are prominent in platelets, milrinone, a PDE III inhibitor, and zaprinast, a PDE V inhibitor, were tested alone and in the presence of NO for their effect on aggregation. Aggregometry was performed on rabbit platelet-rich plasma following addition of ADP as agonist. Milrinone alone gave an IC50 of 12.4 μM. With each agent set to give suboptimal inhibition of aggregation, the combination of milrinone (3-16 μM) and NO (2-10 μM) produced a greater effect than either agent alone. Zaprinast exhibited no effect on aggregation in concentrations up to 160 μM. However, adding zaprinast to 2 μM NO, which alone reduced aggregation ∼30%, produced a marked synergism in the inhibitory effect up to and including no observable aggregation. These results indicate that elevation of either cAMP or cGMP is sufficient to inhibit platelet function. The platelet cAMP concentration appears high enough to be inhibitory when degradation is suppressed by milrinone. However, basal cGMP levels must be increased by NO before the zaprinast effect is observed.

UR - http://www.scopus.com/inward/record.url?scp=0031204010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031204010&partnerID=8YFLogxK

M3 - Article

C2 - 9261901

AN - SCOPUS:0031204010

VL - 8

SP - 115

EP - 118

JO - Shock

JF - Shock

SN - 1073-2322

IS - 2

ER -